Towards integrated, multi-scale supply chains

迈向一体化、多规模供应链

• 批准号: 2744781
• 金额: --
• 依托单位: Imperial College London
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2744781
• 关键词: Towards; integrated; multi; scale; supply

The general milestones of this project will be:1. Integration of the large-scale end-to-end cell and gene therapy supply chain including plasmid DNA, viral vectors and cell therapies. This will be done by, firstly, building the multi-period supply chain optimisation problem for plasmid DNA. The next step is to integrate the optimisation models for plasmid DNA, viral vectors and cell therapies in a single-leader-multiple-follower supply chain model (game theory) (1st year).2. Solution methodologies for the final end-to-end cell and gene therapy supply chain based on decomposition techniques, such as matheuristics, metaheuristics and artificial intelligence (1st and 2nd year).3. Real-time online (closed loop) optimisation for the cell and gene therapy supply chain where optimisation events respond to system disturbances such as product failure and criticality of the patient condition (2nd and 3rd year).4. Assess the transferability of the proposed framework to other supply chains (e.g energy) (3rd year).

该项目的总体里程碑将是：1。整合大规模的端到端细胞和基因治疗供应链，包括质粒DNA、病毒载体和细胞疗法。这将首先通过构建质粒DNA的多周期供应链优化问题来完成。下一步是将质粒DNA，病毒载体和细胞疗法的优化模型整合到一个单一领导者-多个追随者的供应链模型（博弈论）中（第1年）。基于分解技术的最终端到端细胞和基因治疗供应链的解决方案方法，如数学，元分析和人工智能（第一和第二年）。细胞和基因治疗供应链的实时在线（闭环）优化，其中优化事件响应系统干扰，如产品故障和患者病情的危急程度（第2年和第3年）。4.评估拟议框架向其他供应链（如能源）的可转移性（第三年）。